Growth Narrative Undermined by Soft Year-on-Year Result
Management projects strong momentum — 62% disbursement growth, 28% profit growth quarter-on-quarter — but reported revenue fell 17.8% year-on-year. The quarter marks a recovery from Q1, not a beat of prior year.
₹312.3 Cr
+28% QoQ, +1.3% YoY
₹1,850 Cr
+12% QoQ, −17.8% YoY
₹6,278 Cr
+62% QoQ; H1 total ₹10,123 Cr
0.15%
Down from 0.21% (Q1)
The quarter reads as a split verdict. Quarter-on-quarter, the story is momentum: disbursements surged 62%, profit grew 28%, and asset quality improved materially. But year-on-year, it is a soft result. Revenue fell 17.8% and profit barely budged (+1.3%). This gap tells the real story: Q2 FY26 was a significantly higher base, and Sammaan is still exiting a trough, not yet beating prior-year levels despite management's confident transformation narrative.
What the numbers actually say
Implied Q2 FY26 revenue was approximately ₹2,250 Cr (back-calculating from the 17.8% YoY decline). This quarter at ₹1,850 Cr represents a step down from that prior-year level. PAT at ₹312.3 Cr is essentially flat versus prior year (₹308.3 Cr), despite the 28% QoQ jump from Q1's ₹243 Cr. The quarter-on-quarter recovery is real — it reflects a turnaround from Q1 weakness — but the year-on-year lens reveals that Sammaan is still normalizing after a prior-year peak, not accelerating into new growth.
30% profit growth in quarter
PBT grew 30% QoQ (₹326 Cr → ₹425 Cr); PAT grew 28% QoQ (₹243 Cr → ₹312 Cr)
Supported (QoQ basis)
Improving asset quality significantly
Gross NPA fell to 0.15% from 0.21%; net NPA to 0.11% from 0.15%
Supported
62% disbursement growth in quarter
Disbursements ₹6,278 Cr, up 62% QoQ from ₹3,885 Cr (Q1)
Supported
Cost of funds declining trajectory
Cost of funds 9.8% at Q2; target 9.3%; stated as declining despite rising rates
Partial (behind target, timeline extended)
Transformation to growth phase underway
AUM up QoQ but revenue down 17.8% YoY; PAT up only 1.3% YoY despite 28% QoQ growth
Overstated (this is recovery, not outgrowth)
What changed on this call
Product expansion is now concrete. Gold loans policy approved; soft launch in 16 branches during Q3, commercial rollout to 30+ branches in Q4. Personal loans via 20 identified branches (average ticket ₹2 lakh, yield 16–17%). Business installment loans targeting MSME segment (average ticket ₹18–20 lakh, yield 14–18%). Previously, Sammaan's franchise was mortgages + commercial real estate. The multi-product strategy is no longer a blue-sky plan—it is in motion.
Capital support from IHC strengthening. The first warrant tranche (₹906 Cr) converted by October 30, 2026, raising IHC stake from 28.34% to 33.32%. Second tranche (₹2,291 Cr) due by September 2027. This capital infusion is tangible; it funded the Q2 AUM growth and branch expansion (now 245 branches, targeting 300 by FY27 year-end). It also signals confidence from the parent and reduces Sammaan's cost of capital relative to standalone NBFCs.
Cost of funds trajectory revised slightly. Management guided to 9.3% but is currently at 9.8%. The company cited recent USD150 million funding from a UAE bank (IHC-related) at competitive rates, with another similar-sized transaction expected in H2. This is a deliberate move to access cheaper funding pools outside the domestic market. However, the RBI's repo rate cycle remains uncertain, and the target remains a forecast, not a done deal.
Revenue growth turned negative year-on-year. This is a downgrade from the prior trajectory. Prior guidance implied growth, but Q2 FY27 revenue −17.8% YoY signals a pullback or a normalizing cycle. Management did not adjust full-year guidance (₹70,700 Cr AUM, ₹30,100 Cr disbursement, ₹1,400 Cr PAT by FY27 year-end), but the YoY softness raises execution risk for H2.
How the street is positioned
Price action reflects deep skepticism. Sammaan trades at ₹131.29, down 89.77% from its all-time high (₹1,283.60). This drawdown occurred over a period longer than 52 weeks, signaling that the market's loss of confidence predates Q2. Currently, the stock trades below its 50-day average (₹134.15) and 200-day average (₹150.19), with RSI at 50.5 (neutral). The 52-week range is ₹111.55–₹192.34; the current price sits in the middle of that range, but well below the 200-day average.
Institutions are trimming. FII ownership fell to 19.50% in Q3 FY27 from 21.34% in Q2 FY27 (−1.84 percentage points). DII ownership slipped from 4.17% to 3.89% (−0.28 pp). Meanwhile, promoter stake rose from 28.39% to 33.37% (+4.98 pp), driven by the first warrant tranche conversion by IHC. The pattern is clear: foreign investors are selling into any rally, while the parent company is building its stake. This suggests institutional skepticism that the new product initiatives and cost-of-capital advantages will translate into near-term earnings accretion.
Valuation context. The stock's massive drawdown from all-time high reflects the market's repricing of risk over the long term. At ₹131.29, it is off the 52-week low by 17.7%, a small rally into Q2 results, but this has not held. The question for holders is whether the drawdown is opportunistic (a turnaround play with execution risk) or prescient (a business model challenged by rate cycles and competition). Q2's soft YoY result lends credence to the latter view.
The bull-bear ledger
Parent company backing (IHC) provides cost-of-capital advantage over standalone NBFCs; ₹3,197 Cr capital pipeline de-risks near-term leverage needs
Asset quality materially improved (gross NPA 0.15%, down from 0.21%); collection efficiency 99.6%
Disbursement growth 62% QoQ is tangible momentum; H1 disbursements tracking at 33.6% of full-year target
Branch network expansion (245 → 300 by FY27) ongoing; retail lending market growing 19% CAGR; Sammaan targeting 2% share via multi-product strategy
Long-term leverage target 4.5x by 2030 (vs. current 3.0x) leaves ample room for growth without raising capital concerns
Revenue down 17.8% YoY despite confident 'transformation to growth phase' narrative; this is recovery from Q1 trough, not outgrowth
PAT grew only 1.3% YoY; full-year target ₹1,400 Cr requires ₹844 Cr PAT in H2 (60.3% of target), a tight pace
Cost of funds 9.8% vs. 9.3% target; RBI rate cycle uncertain; margin compression risk if lending rate pass-through lags CoF increases
New product execution (gold loans, personal loans, business loans) unproven at scale; soft launches Q3–Q4 add near-term execution risk
FII selling into rallies (down 1.84 pp QoQ) signals institutional skepticism on earnings visibility
Stock down 89.77% from all-time high; market has priced in deep skepticism; burden of proof is on management to execute
Ranked risks — by how much they should concern a holder
Year-on-year revenue decline (Q2 FY27 −17.8% YoY)
HighSignals prior-year (Q2 FY26) was significantly higher at ~₹2,250 Cr. Despite confident call narrative, Sammaan has not yet beaten prior-year levels. This suggests cyclical trough exit or structural market share loss, not growth acceleration. If H2 disbursements/revenue do not reaccelerate, the full-year targets will be missed.
H2 pacing very tight to hit full-year targets
HighFY27 PAT target ₹1,400 Cr with H1 at ₹556 Cr requires ₹844 Cr in H2 (60% of target). Disbursement target ₹30,100 Cr with H1 at ₹10,123 Cr requires ₹19,977 Cr in H2 (66% of target). These paces demand H2 acceleration or new product contributions; execution miss would signal management guidance was overstated.
New product execution risk (gold loans, personal loans, business loans scale-up)
MediumGold loans soft launch Q3 (16 branches), commercial rollout Q4 (30+ branches). Personal loans via 20 branches; business loans targeting MSME. All are new, unproven products at scale. Any misstep (credit quality, operational capacity, market demand) would derail the multi-product growth narrative and push targets further behind.
Cost of funds trajectory at risk; margin compression in rising-rate environment
MediumCost of funds is 9.8% vs. 9.3% target. RBI rate cycle is uncertain. If rates rise further, funding costs climb. If lending rate pass-through lags, net interest margins compress. Management claims spreads will hold, but this is execution-dependent and unproven at scale in a tightening cycle.
Branch expansion execution (245 → 300, +22% in 6 months)
MediumH1 added 28 branches and 1,123 employees (87% deployed at branches). Pacing to 300 by FY27 year-end requires 55+ more branches and continued hiring. Operational discipline is critical; any misstep in talent deployment or operational systems could drag asset quality or margins.
FII selling into rallies; institutional skepticism on visibility
MediumFII stake fell from 21.34% to 19.50% QoQ. This suggests large holders do not believe earnings visibility supports a rally. If more institutions trim on any bounce, liquidity could tighten and valuation multiple could compress further.
Dependence on IHC capital infusions; warrant conversion timelines and dilution
MediumIHC has committed ₹3,197 Cr via warrant conversion, but it is split across two tranches (₹906 Cr done, ₹2,291 Cr by September 2027). Delay in second tranche would pressure capital adequacy and growth plans. Each tranche also dilutes existing shareholders; promoter stake rising from 28% to 43% by September 2027.
The debate
What to watch next
1 · Q3 gold loan soft launch and personal loan origination traction
Gold loans in 16 branches and personal loans via 20 branches are the proof points. If these products show early traction in originations, collection, and spreads, the multi-product narrative gains credibility. If uptake is slow or margins disappointing, it signals execution risk remains and new growth avenues are unproven.
2 · H2 FY27 disbursement and AUM pacing vs. full-year targets
FY27 disbursement target ₹30,100 Cr requires ₹19,977 Cr in H2 (66% of annual). AUM target ₹70,700 Cr requires ₹11,512 Cr in H2. If H2 Q's track above 50% of target pace, management's confidence holds and targets are credible. If H2 disbursements fall short, it validates the market's view that guidance is optimistic and YoY weakness persists.
3 · Cost of funds progression and margin trajectory
Cost of funds is 9.8% vs. 9.3% target. If Q3 shows movement toward 9.3%, it signals the UAE bank funding strategy is working and margin headwinds are easing. If CoF remains stuck above 9.5%, it signals funding cost pressures persist despite parent support, and NIM expansion will lag guidance.
The number to track
Adjusted PAT (excluding fair value accounting gains and securitization derecognition gains). Reported Q2 PAT is ₹312.3 Cr, but fair value volatility and ₹7 Cr derecognition gains add noise. Underlying organic PAT is the driver of intrinsic value. If H2 Q's show adjusted PAT tracking at ~50%+ of the ₹1,400 Cr FY27 target (₹~700 Cr H2 total, or ~₹350 Cr per quarter), the turnaround narrative holds. If adjusted PAT slips further, the market's skepticism is justified.
Sammaan Q2 is a quarter of recovery, not outgrowth. Management is executing on product expansion and parent capital is real, but the soft year-on-year result — revenue down 17.8%, profit up only 1.3% — contradicts the confident transformation narrative. The market's 89.77% drawdown from all-time high reflects this skepticism. For holders, the question is execution: can H2 disbursements and profitability reaccelerate to meet targets, and do new products prove out? Asset quality is genuinely improving, and parent backing is a structural advantage. But until the top line beats prior year and profit acceleration is organic (not dependent on market timing or one-time gains), this remains a 'show me' story, not a conviction hold.
Informational and educational content only. Not investment advice.